A few tumor-specific proteins that act as leukemia-specific antigens (Tumor Specific Antigens, TSA), such as RUNX1-RUNX1T1, FLT3, and NPM1, have been described as being associated with AML (229), resulting from mutations (mutated TSA) or aberrant expression (aberrantly expressed TSA) from noncoding regions (230). This evidence concerns the gene FLT3 and acute myeloid leukemia.